Methyldopa
Methyldopa
- Drug class
- Methyldopa
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 31
Overview
Methyldopa is an active pharmaceutical ingredient in the Methyldopa group (C02AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 28 | May 29, 2026 |
| CA Canada | Health Canada | 3 | May 8, 2025 |
GBUnited Kingdom· MHRA
28 products
Uses
In the treatment of hypertension
How to take
CACanada· Health Canada
3 products
Uses
METHYLDOPA (methyldopa tablets) is indicated: • For the treatment of arterial hypertension. May be employed in a general treatment program in conjunction with a diuretic and/or other antihypertensive drugs as needed for proper response in patients with hypertension of various severity.
• As the initial agent in the treatment of hypertension in those patients for which treatment should not be started with a diuretic. 1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of methyldopa tablets in pediatric patients has been established; therefore, Health Canada has authorized an indication for pediatric use.
2 Recommended Dose and Dosage Adjustment, Pediatrics. 2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.
2 Recommended Dose and Dosage Adjustment, Geriatrics.
Drug interactions
Known interactions involving Methyldopa. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 289. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL334140060 · revised June 21, 2024
- [2]Health Canada (DPD) · 00360252 · revised May 8, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.